Study Updates, Notices, Quarterly Reports, and Revenue Guidance Updates - Research Report on NPS Pharmaceuticals, Oramed,

  Study Updates, Notices, Quarterly Reports, and Revenue Guidance Updates -
Research Report on NPS Pharmaceuticals, Oramed, PAREXEL, PhotoMedex, and Cell
                                 Therapeutics

Editor Note: For more information about this release, please scroll to bottom.

PR Newswire

NEW YORK, January 7, 2014

NEW YORK, January 7, 2014 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting NPS
Pharmaceuticals, Inc. (NASDAQ: NPSP), Oramed Pharmaceuticals Inc. (NASDAQ:
ORMP), PAREXEL International Corporation (NASDAQ: PRXL), PhotoMedex, Inc.
(NASDAQ: PHMD), and Cell Therapeutics, Inc. (NASDAQ: CTIC). Today's readers
may access these reports free of charge - including full price targets,
industry analysis and analyst ratings - via the links below.

NPS Pharmaceuticals, Inc. Research Report

On January 2, 2014, NPS Pharmaceuticals, Inc. (NPS Pharmaceuticals) announced
that it has initiated a global registration study of teduglutide in pediatric
patients with Short Bowel Syndrome (SBS) who are dependent on parenteral
support. According to NPS Pharmaceuticals, the 12-week, open-label study
evaluating teduglutide will be conducted at sites throughout US and Europe,
and is expected to enroll up to 36 patients. Roger Garceau, MD, FAAP,
Executive Vice President and Chief Medical Officer of NPS Pharmaceuticals,
commented, "We are particularly proud to advance teduglutide in pediatric
Short Bowel Syndrome, as it may bring us one step closer to fulfilling a
significant unmet need among children across the globe who face a life
burdened by this rare disease." Garceau added, "We look forward to reporting
top line results following the completion of the study in late 2014 or early
2015." The Full Research Report on NPS Pharmaceuticals, Inc. - including full
detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:

http://www.AnalystsCorner.com/r/full_research_report/441a_NPSP

Oramed Pharmaceuticals Inc. Research Report

On January 2, 2014, Oramed Pharmaceuticals Inc. (Oramed) announced that it has
received Notices of Allowance from the Israel and Australian Patent Offices
for "Methods and Compositions for Oral Administrations of Proteins." Oramed
reported that the patent covers a core concept of platform technology in oral
delivery of proteins which are currently delivered through injection. The
Company stated that the allowance in Israel marks the second from the Israel
Patent Office in the past 30 days and the second Australian patent allowance
since the grant of a different patent in May 2012. Oramed further informed
that the said patent has also been approved in Japan, China, Russia, and New
Zealand. The Full Research Report on Oramed Pharmaceuticals Inc. - including
full detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:

http://www.AnalystsCorner.com/r/full_research_report/c199_ORMP

PAREXEL International Corporation Research Report

On January 2, 2014, PAREXEL International Corporation (PAREXEL) announced that
it will release its Q2 FY 2014 results after the stock market close on
Wednesday, January 29, 2014. PAREXEL reported that the conference call and
live webcast will be held on Thursday, January 30, 2013 at 10:00 a.m. ET. The
Company further noted that the live webcast and replay will be accessible
through the Investors menu on its website for one year. The Full Research
Report on PAREXEL International Corporation - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at:

http://www.AnalystsCorner.com/r/full_research_report/067b_PRXL

PhotoMedex, Inc. Research Report

On January 2, 2014, PhotoMedex, Inc. (PhotoMedex) revised its Q4 2013 revenue
guidance, expecting revenues to be more than $60 million without any
contribution from Japan, compared with prior guidance of more than $55 million
without any contribution from Japan. According to PhotoMedex, the Q4 2013
revenue outperformance is primarily attributable to holiday advertising in the
Consumer business segment that yielded global direct response sales above
prior forecasts, and also to better-than-expected sales to retail and home
shopping channel customers. Dr. Dolev Rafaeli, CEO of PhotoMedex, said,
"Consumer demand for no!no! is strong and our advertising spend for the new
no!no! Pro during the Christmas holiday season generated a very high media
efficiency ratio. In other positive developments, we are experiencing strong
patient response to our XTRAC advertising campaign in major markets. We are
pleased that for the fourth consecutive quarter XTRAC treatment revenues grew
by more than 50% over the prior-year comparison, and for the 12 months ended
December 31, 2013 grew by more than 80% over the prior year." PhotoMedex noted
that intends to release its Q4 2013 results in mid-March 2014. The Full
Research Report on PhotoMedex, Inc. - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
at:

http://www.AnalystsCorner.com/r/full_research_report/bcc6_PHMD

Cell Therapeutics, Inc. Research Report

On January 2, 2014, Cell Therapeutics, Inc. (Cell Therapeutics) received a
notification from the US Food and Drug Administration (FDA), which notifies
that the partial clinical hold on tosedostat (IND 075503) has been removed and
all ongoing studies may continue. According to Cell Therapeutics, Tosedostat
is currently being studied in the US and European Union in
investigator-sponsored and cooperative group-sponsored Phase 2 trials in
elderly patients with newly diagnosed and relapsed acute myeloid leukemia
(AML) and high-risk myelodysplastic syndromes (MDS). "We are pleased that the
FDA has responded favorably to the tosedostat clinical trial data provided and
removed the partial clinical hold to allow further development of tosedostat
in ongoing and future studies," commented John Pagel, MD, PhD, Associate
Member, Clinical Research Division, Fred Hutchinson Cancer Research Center;
Associate Professor, Medical Oncology Division, University of Washington
School of Medicine; and Principal Investigator in the tosedostat first-line
AML/MDS trial. The Full Research Report on Cell Therapeutics, Inc. - including
full detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:

http://www.AnalystsCorner.com/r/full_research_report/f9df_CTIC

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are
    only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Ananya Ghosh, CFA, has
only reviewed the information provided by Equity News Network in this article
or report according to the Procedures outlined by Equity News Network. Equity
News Network is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

http://www.AnalystsCorner.com

SOURCE Analysts' Corner

Contact: Joe Thomas, +1-310-496-8071 (North America)
 
Press spacebar to pause and continue. Press esc to stop.